COVID-19 in adult acute myeloid leukemia patients: A long-term followup study from the European Hematology Association survey (EPICOVIDEHA)
Pathology and Laboratory Medicine
Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p.
Ali, N. B.
(2022). COVID-19 in adult acute myeloid leukemia patients: A long-term followup study from the European Hematology Association survey (EPICOVIDEHA). Haematologica.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/1398